Nautilus Biotechnology enters agreement with Allen Institute

Nautilus Biotechnology (NAUT) announced they have entered into an agreement with the Allen Institute focused on investigating the connection between the tau protein and neurodegenerative conditions such as Alzheimer’s disease. This further validates the importance and potential of novel single-molecule proteomic data like that shared in Nautilus’ recent preprint. “We are pleased to partner with the Allen Institute to answer highly impactful questions about the role of tau proteoforms in Alzheimer’s disease and to further demonstrate the critical role that single-molecule protein analysis may play in advancing the development of new diagnostics and treatments,” said Parag Mallick, Ph.D., co-founder and Chief Scientist of Nautilus. “Our Iterative Mapping approach is generating excitement from the wider scientific community which sees it as an entirely new class of measurement-a fundamentally different way to understand biology-and we are thrilled to continue pushing the frontiers of proteomics with pioneers like the researchers at the Allen Institute.”